Patents by Inventor Edward Brnardic

Edward Brnardic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MRGX2 ANTAGONISTS
    Publication number: 20220112174
    Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.
    Type: Application
    Filed: October 4, 2021
    Publication date: April 14, 2022
    Inventors: Edward BRNARDIC, Michael BURY, Rodolfo CADILLA, Jon COLLINS, Yu GUO, Anthony HANDLON, Huijie LI, Yue LI, Daniel PAONE, Christie SCHULTE, Barry SHEARER, Guosen YE, Maben YING, Huichang ZHANG
  • TrkA kinase inhibitors, compositions and methods thereof
    Patent number: 9181261
    Abstract: The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: November 10, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shawn J. Stachel, Melissa Egbertson, Edward Brnardic, Kristen G. Jones, John M. Sanders, Darrell Henze
  • TrkA Kinase Inhibitors, Compositions and Methods Thereof
    Publication number: 20150141428
    Abstract: The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Shawn J. Stachel, Melissa Egbertson, Edward Brnardic, Kristen G. Jones, John M. Sanders, Darrell Henze
  • 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES
    Publication number: 20100292241
    Abstract: The present invention is directed to 3,5-disubstituted-1,3-oxazolidin-2-one derivatives which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neuro-ological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: January 14, 2009
    Publication date: November 18, 2010
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Edward Brnardic, Mark Fraley, Mark Layton, Robert Garbaccio